{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,13]],"date-time":"2026-07-13T15:45:00Z","timestamp":1783957500376,"version":"3.55.0"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T00:00:00Z","timestamp":1718323200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Palliat Care"],"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>Clinical evidence for the rapidity and effectiveness of fentanyl buccal soluble film (FBSF) in reducing pain intensity of breakthrough cancer pain (BTcP) remains inadequate. This study aimed to evaluate the efficacy of FBSF proportional to the around-the\u2010clock (ATC) opioid regimens in rapidly relieving the intensity of BTcP episodes by determining the percentage of patients requiring further dose titration.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>The study procedure included a dose-finding period followed by a 14-day observation period. Pain intensity was recorded with a Numeric Rating Scale (NRS) at onset and 5, 10, 15, and 30\u00a0min after FBSF self-administration. Meaningful pain relief was defined as the final NRS score\u2009\u2264\u20093. Satisfaction survey was conducted for each patient after treatment using the Global Satisfaction Scale.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>A total of 63 BTcP episodes occurred in 30 cancer patients. Only one patient required rescue medication at first BTcP episode and then achieved meaningful pain relief after titrating FBSF by 200\u00a0\u00b5g. Most BTcP episodes relieved within 10\u00a0min. Of 63 BTcP episodes, 30 (47.6%), 46 (73.0%), and 53 (84.1%) relieved within 5, 10, and 15\u00a0min after FBSF administration. Only grade 1\/2 adverse events were reported, including somnolence, malaise, and dizziness. Of the 63 BTcP episodes, 82.6% were rated as excellent\/good satisfaction with FBSF.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>FBSF can be administrated \u201con demand\u201d by cancer patients at the onset of BTcP, providing rapid analgesia by achieving meaningful pain relief within 10\u00a0min.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Trial registration<\/jats:title>\n                <jats:p>This study was retrospectively registered 24 December, 2021 at Clinicaltrial.gov (NCT05209906): <jats:ext-link xmlns:xlink=\"http:\/\/www.w3.org\/1999\/xlink\" ext-link-type=\"uri\" xlink:href=\"https:\/\/clinicaltrials.gov\/study\/NCT05209906\">https:\/\/clinicaltrials.gov\/study\/NCT05209906<\/jats:ext-link>.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s12904-024-01483-7","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:02:36Z","timestamp":1718341356000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Effectiveness of fentanyl buccal soluble film in cancer patients with inadequate breakthrough pain control"],"prefix":"10.1186","volume":"23","author":[{"given":"Yi-Hao","family":"Chiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ching-Ting","family":"Lien","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen-Hao","family":"Su","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tsung-Yu","family":"Yen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yu-Jen","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuen-Liang","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ken-Hong","family":"Lim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kun-Yao","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hsin-Pei","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chia-Yen","family":"Hung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yi-Shing","family":"Leu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,6,14]]},"reference":[{"key":"1483_CR1","doi-asserted-by":"crossref","unstructured":"Cuomo A, Boutis A, Colonese F, Nocerino D. High-rate breakthrough cancer pain and tumour characteristics - literature review and case series. Drugs Context 2023, 12.","DOI":"10.7573\/dic.2022-11-1"},{"issue":"Suppl 4","key":"1483_CR2","doi-asserted-by":"publisher","first-page":"iv166","DOI":"10.1093\/annonc\/mdy152","volume":"29","author":"M Fallon","year":"2018","unstructured":"Fallon M, Giusti R, Aielli F, Hoskin P, Rolke R, Sharma M, Ripamonti CI, Committee EG. Management of cancer pain in adult patients: ESMO Clinical Practice guidelines. Ann Oncol. 2018;29(Suppl 4):iv166\u201391.","journal-title":"Ann Oncol"},{"key":"1483_CR3","doi-asserted-by":"publisher","first-page":"153473541985909","DOI":"10.1177\/1534735419859095","volume":"18","author":"S Gonella","year":"2019","unstructured":"Gonella S, Sperlinga R, Sciannameo V, Dimonte V, Campagna S. Characteristics of breakthrough Pain and its impact on quality of life in terminally Ill Cancer patients. Integr Cancer Ther. 2019;18:1534735419859095.","journal-title":"Integr Cancer Ther"},{"issue":"8","key":"1483_CR4","doi-asserted-by":"publisher","first-page":"943","DOI":"10.2217\/fon-2020-1063","volume":"17","author":"R Hernanz de Lucas","year":"2021","unstructured":"Hernanz de Lucas R, Nunez Fernandez M, Gomez-Caamano A, Morera Lopez R, Fortes de la Torre I, de la Torre Tomas A, Munoz-Garzon V, Lopez Bermudo C, Manas Rueda A. Quality of life in patients with breakthrough cancer pain in radiation oncology departments in Spain: the CAVIDIOR study. Future Oncol. 2021;17(8):943\u201354.","journal-title":"Future Oncol"},{"issue":"5","key":"1483_CR5","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3390\/cancers13051058","volume":"13","author":"S Mercadante","year":"2021","unstructured":"Mercadante S, Maltoni M, Russo D, Adile C, Ferrera P, Rossi R, Rosati M, Casuccio A. The prevalence and characteristics of breakthrough Cancer Pain in patients receiving low doses of opioids for background Pain. Cancers (Basel). 2021;13(5):1058.","journal-title":"Cancers (Basel)"},{"key":"1483_CR6","doi-asserted-by":"publisher","first-page":"2349","DOI":"10.2147\/JPR.S203903","volume":"12","author":"C Camps Herrero","year":"2019","unstructured":"Camps Herrero C, Anton Torres A, Cruz-Hernandez JJ, Carrato A, Constenla M, Diaz-Rubio E, Feyjoo Saus M, Garcia-Foncillas J, Gascon P, Guillem V. Working towards a consensus on the oncological approach of breakthrough pain: a Delphi survey of Spanish experts. J Pain Res. 2019;12:2349\u201358.","journal-title":"J Pain Res"},{"issue":"1","key":"1483_CR7","doi-asserted-by":"publisher","first-page":"17701","DOI":"10.1038\/s41598-019-54195-x","volume":"9","author":"C Perez-Hernandez","year":"2019","unstructured":"Perez-Hernandez C, Blasco A, Gandara A, Manas A, Rodriguez-Lopez MJ, Martinez V, Fernandez-Nistal A, Montoto C. Prevalence and characterization of breakthrough pain in patients with cancer in Spain: the CARPE-DIO study. Sci Rep. 2019;9(1):17701.","journal-title":"Sci Rep"},{"key":"1483_CR8","first-page":"4325271","volume":"2018","author":"LM Torres","year":"2018","unstructured":"Torres LM, Jimenez AJ, Cabezon A, Rodriguez MJ. Prevalence and characterization of breakthrough Pain Associated with Chronic Low Back Pain in the South of Spain: a cross-sectional, Multicenter, Observational Study. Pain Res Treat. 2018;2018:4325271.","journal-title":"Pain Res Treat"},{"issue":"1","key":"1483_CR9","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s12325-013-0086-4","volume":"31","author":"I Velazquez Rivera","year":"2014","unstructured":"Velazquez Rivera I, Munoz Garrido JC, Garcia Velasco P, Espana Ximenez de Enciso I, Velazquez Clavarana L. Efficacy of sublingual fentanyl vs. oral morphine for cancer-related breakthrough pain. Adv Ther. 2014;31(1):107\u201317.","journal-title":"Adv Ther"},{"issue":"2","key":"1483_CR10","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/S0885-3924(00)00161-5","volume":"20","author":"G Zeppetella","year":"2000","unstructured":"Zeppetella G, O\u2019Doherty CA, Collins S. Prevalence and characteristics of breakthrough pain in cancer patients admitted to a hospice. J Pain Symptom Manage. 2000;20(2):87\u201392.","journal-title":"J Pain Symptom Manage"},{"key":"1483_CR11","unstructured":"Bennett D, Burton AW, Fishman S, Fortner B, McCarberg B, Miaskowski C, Nash DB, Pappagallo M, Payne R, Viscusi ER et al. Consensus panel recommendations for the assessment and management of breakthrough pain PART 2 MANAGEMENT. P&T 2005, 30(6):354\u2013361."},{"key":"1483_CR12","doi-asserted-by":"publisher","first-page":"893530","DOI":"10.3389\/fpain.2022.893530","volume":"3","author":"P Bossi","year":"2022","unstructured":"Bossi P, Escobar Y, Pea F. Rapid-Onset opioids for management of breakthrough Cancer Pain: considerations for Daily Practice. Front Pain Res (Lausanne). 2022;3:893530.","journal-title":"Front Pain Res (Lausanne)"},{"issue":"1","key":"1483_CR13","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1007\/s40199-020-00381-6","volume":"29","author":"M Hashemi","year":"2021","unstructured":"Hashemi M, Zali A, Golmakani E, Delshad MH, Shadnoush M, Akbari ME. Efficacy, safety, and tolerability of sublingual fentanyl orally disintegrating tablet in the treatment of breakthrough cancer pain: a randomized, double-blind, placebo-controlled study. Daru. 2021;29(1):51\u20139.","journal-title":"Daru"},{"issue":"14","key":"1483_CR14","doi-asserted-by":"publisher","first-page":"1717","DOI":"10.2217\/fon-2021-1639","volume":"18","author":"AT Rodriguez","year":"2022","unstructured":"Rodriguez AT, Viejo MN, Maradey P, Canal-Sotelo J, Mancilla PG, Rivero SG, Casillas IR, Abian MH, Bermudo CL. Low-dose sublingual fentanyl improves quality of life in patients with breakthrough cancer pain in palliative care. Future Oncol. 2022;18(14):1717\u201331.","journal-title":"Future Oncol"},{"issue":"4","key":"1483_CR15","doi-asserted-by":"publisher","first-page":"573","DOI":"10.1016\/j.jpainsymman.2012.09.009","volume":"46","author":"R Jandhyala","year":"2013","unstructured":"Jandhyala R, Fullarton JR, Bennett MI. Efficacy of rapid-onset oral fentanyl formulations vs. oral morphine for cancer-related breakthrough pain: a meta-analysis of comparative trials. J Pain Symptom Manage. 2013;46(4):573\u201380.","journal-title":"J Pain Symptom Manage"},{"issue":"2","key":"1483_CR16","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1136\/bmjspcare-2011-000139","volume":"2","author":"R Jandhyala","year":"2012","unstructured":"Jandhyala R, Fullarton J. Various formulations of oral transmucosal fentanyl for breakthrough cancer pain: an indirect mixed treatment comparison meta-analysis. BMJ Support Palliat Care. 2012;2(2):156\u201362.","journal-title":"BMJ Support Palliat Care"},{"issue":"5","key":"1483_CR17","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1007\/s40261-016-0394-y","volume":"36","author":"KP Garnock-Jones","year":"2016","unstructured":"Garnock-Jones KP. Fentanyl Buccal Soluble Film: a review in breakthrough Cancer Pain. Clin Drug Investig. 2016;36(5):413\u20139.","journal-title":"Clin Drug Investig"},{"key":"1483_CR18","unstructured":"ONSOLIS [package insert]. Raleigh, NC: IBSI Inc; 2016."},{"issue":"6","key":"1483_CR19","doi-asserted-by":"publisher","first-page":"1308","DOI":"10.1093\/annonc\/mdp541","volume":"21","author":"R Rauck","year":"2010","unstructured":"Rauck R, North J, Gever LN, Tagarro I, Finn AL. Fentanyl buccal soluble film (FBSF) for breakthrough pain in patients with cancer: a randomized, double-blind, placebo-controlled study. Ann Oncol. 2010;21(6):1308\u201314.","journal-title":"Ann Oncol"},{"issue":"7","key":"1483_CR20","doi-asserted-by":"publisher","first-page":"1017","DOI":"10.1111\/j.1526-4637.2010.00875.x","volume":"11","author":"N Vasisht","year":"2010","unstructured":"Vasisht N, Gever LN, Tagarro I, Finn AL. Single-dose pharmacokinetics of fentanyl buccal soluble film. Pain Med. 2010;11(7):1017\u201323.","journal-title":"Pain Med"},{"issue":"1","key":"1483_CR21","doi-asserted-by":"publisher","first-page":"63","DOI":"10.2165\/11594670-000000000-00000","volume":"32","author":"AL Finn","year":"2012","unstructured":"Finn AL, Vasisht N, Stark JG, Gever LN, Tagarro I. Dose proportionality and pharmacokinetics of fentanyl buccal soluble film in healthy subjects: a phase I, open-label, three-period, crossover study. Clin Drug Investig. 2012;32(1):63\u201371.","journal-title":"Clin Drug Investig"},{"issue":"30","key":"1483_CR22","doi-asserted-by":"publisher","first-page":"e11593","DOI":"10.1097\/MD.0000000000011593","volume":"97","author":"TY Yen","year":"2018","unstructured":"Yen TY, Chiou JF, Chiang WY, Su WH, Huang MY, Hu MH, Wu SC, Lai YL. Proportional dose of rapid-onset opioid in breakthrough cancer pain management: an open-label, multicenter study. Med (Baltim). 2018;97(30):e11593.","journal-title":"Med (Baltim)"},{"issue":"5","key":"1483_CR23","doi-asserted-by":"publisher","first-page":"e1179","DOI":"10.1002\/cnr2.1179","volume":"2","author":"TJ Chiou","year":"2019","unstructured":"Chiou TJ, Chao TC, Chao TY, Huang JS, Chang YF, Wang CH. A dose titration study of fentanyl buccal soluble film for breakthrough cancer pain in Taiwan. Cancer Rep (Hoboken). 2019;2(5):e1179.","journal-title":"Cancer Rep (Hoboken)"},{"key":"1483_CR24","doi-asserted-by":"publisher","first-page":"245","DOI":"10.2147\/JPR.S22641","volume":"4","author":"AL Finn","year":"2011","unstructured":"Finn AL, Hill WC, Tagarro I, Gever LN. Absorption and tolerability of fentanyl buccal soluble film (FBSF) in patients with cancer in the presence of oral mucositis. J Pain Res. 2011;4:245\u201351.","journal-title":"J Pain Res"},{"key":"1483_CR25","unstructured":"Common Terminology Criteria for Adverse Events. (CTCAE) [https:\/\/ctep.cancer.gov\/protocolDevelopment\/electronic_applications\/ctc.htm#ctc_50]."},{"issue":"4","key":"1483_CR26","doi-asserted-by":"publisher","first-page":"914","DOI":"10.1200\/JCO.22.02198","volume":"41","author":"JA Paice","year":"2023","unstructured":"Paice JA, Bohlke K, Barton D, Craig DS, El-Jawahri A, Hershman DL, Kong LR, Kurita GP, LeBlanc TW, Mercadante S, et al. Use of opioids for adults with Pain from Cancer or Cancer Treatment: ASCO Guideline. J Clin Oncol. 2023;41(4):914\u201330.","journal-title":"J Clin Oncol"},{"issue":"8","key":"1483_CR27","doi-asserted-by":"publisher","first-page":"977","DOI":"10.6004\/jnccn.2019.0038","volume":"17","author":"RA Swarm","year":"2019","unstructured":"Swarm RA, Paice JA, Anghelescu DL, Are M, Bruce JY, Buga S, Chwistek M, Cleeland C, Craig D, Gafford E, et al. Adult Cancer Pain, Version 3.2019, NCCN Clinical Practice guidelines in Oncology. J Natl Compr Canc Netw. 2019;17(8):977\u20131007.","journal-title":"J Natl Compr Canc Netw"},{"issue":"12","key":"1483_CR28","doi-asserted-by":"publisher","first-page":"2657","DOI":"10.1097\/j.pain.0000000000000721","volume":"157","author":"S Mercadante","year":"2016","unstructured":"Mercadante S, Portenoy RK. Breakthrough cancer pain: twenty-five years of study. Pain. 2016;157(12):2657\u201363.","journal-title":"Pain"},{"issue":"1","key":"1483_CR29","doi-asserted-by":"publisher","first-page":"14","DOI":"10.4103\/0973-1075.53506","volume":"15","author":"S Mishra","year":"2009","unstructured":"Mishra S, Bhatnagar S, Chaudhary P, Rana SP. Breakthrough cancer pain: review of prevalence, characteristics and management. Indian J Palliat Care. 2009;15(1):14\u20138.","journal-title":"Indian J Palliat Care"},{"issue":"7","key":"1483_CR30","doi-asserted-by":"publisher","first-page":"e0235461","DOI":"10.1371\/journal.pone.0235461","volume":"15","author":"SR Banala","year":"2020","unstructured":"Banala SR, Khattab OK, Page VD, Warneke CL, Todd KH, Yeung SJ. Intranasal fentanyl spray versus intravenous opioids for the treatment of severe pain in patients with cancer in the emergency department setting: a randomized controlled trial. PLoS ONE. 2020;15(7):e0235461.","journal-title":"PLoS ONE"},{"issue":"11","key":"1483_CR31","doi-asserted-by":"publisher","first-page":"2805","DOI":"10.1185\/03007990903336135","volume":"25","author":"S Mercadante","year":"2009","unstructured":"Mercadante S, Radbruch L, Davies A, Poulain P, Sitte T, Perkins P, Colberg T, Camba MA. A comparison of intranasal fentanyl spray with oral transmucosal fentanyl citrate for the treatment of breakthrough cancer pain: an open-label, randomised, crossover trial. Curr Med Res Opin. 2009;25(11):2805\u201315.","journal-title":"Curr Med Res Opin"},{"issue":"4","key":"1483_CR32","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1016\/j.clinthera.2007.04.007","volume":"29","author":"DM Simpson","year":"2007","unstructured":"Simpson DM, Messina J, Xie F, Hale M. Fentanyl buccal tablet for the relief of breakthrough pain in opioid-tolerant adult patients with chronic neuropathic pain: a multicenter, randomized, double-blind, placebo-controlled study. Clin Ther. 2007;29(4):588\u2013601.","journal-title":"Clin Ther"},{"issue":"9","key":"1483_CR33","doi-asserted-by":"publisher","first-page":"805","DOI":"10.1097\/01.ajp.0000210932.27945.4a","volume":"22","author":"RK Portenoy","year":"2006","unstructured":"Portenoy RK, Taylor D, Messina J, Tremmel L. A randomized, placebo-controlled study of fentanyl buccal tablet for breakthrough pain in opioid-treated patients with cancer. Clin J Pain. 2006;22(9):805\u201311.","journal-title":"Clin J Pain"},{"issue":"3","key":"1483_CR34","doi-asserted-by":"publisher","first-page":"S35","DOI":"10.1016\/j.jpain.2005.01.136","volume":"6","author":"J Farrar","year":"2005","unstructured":"Farrar J, Thompson C. Oral transmucosal fentanyl citrate: efficacy in neuropathic pain patients. J Pain. 2005;6(3):S35.","journal-title":"J Pain"},{"issue":"6","key":"1483_CR35","doi-asserted-by":"publisher","first-page":"1058","DOI":"10.3904\/kjim.2018.162","volume":"33","author":"SY Yoon","year":"2018","unstructured":"Yoon SY, Oh J. Neuropathic cancer pain: prevalence, pathophysiology, and management. Korean J Intern Med. 2018;33(6):1058\u201369.","journal-title":"Korean J Intern Med"}],"container-title":["BMC Palliative Care"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-024-01483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12904-024-01483-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12904-024-01483-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T05:03:58Z","timestamp":1718341438000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcpalliatcare.biomedcentral.com\/articles\/10.1186\/s12904-024-01483-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,6,14]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1483"],"URL":"https:\/\/doi.org\/10.1186\/s12904-024-01483-7","relation":{},"ISSN":["1472-684X"],"issn-type":[{"value":"1472-684X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,6,14]]},"assertion":[{"value":"1 November 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 June 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 June 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study protocol was approved by the Institutional Review Board of Mackay Memorial Hospital (IRB number: 19MMHIS032e) and was conducted in accordance with the Declaration of Helsinki. This study was retrospectively registered on ClinicalTrials.gov (NCT05209906||; December 24, 2021). This study conforms to the International Committee of Medical Journal Editors (ICMJE). Written informed consent was obtained from all patients prior to participation of this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"All authors declare that there is no conflict of interest.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"150"}}